Targeting KRAS-Mutated NSCLC: Novel TKIs and Beyond.

Cantor, David J; Aggarwal, Charu

Cantor, David J; Aggarwal, Charu.

Afiliación

Cantor DJ; Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Aggarwal C; Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

Clin Cancer Res ; 29(18): 3563-3565, 2023 09 15.

Article en En | MEDLINE | ID: mdl-37466928

RESUMEN

KRAS-mutated non-small cell lung cancer (NSCLC) is the most common genetically altered subtype of NSCLC, yet targeted therapies remain limited. Multiple studies have investigated combinations of MEK inhibitors with chemotherapy without success. Here we discuss these studies and novel approaches to targeting KRAS-mutated NSCLC. See related article by Gadgeel et al., p. 3641.

Asunto(s)

Carcinoma de Pulmón de Células no Pequeñas; Neoplasias Pulmonares; Humanos; Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico; Carcinoma de Pulmón de Células no Pequeñas/genética; Docetaxel/uso terapéutico; Neoplasias Pulmonares/tratamiento farmacológico; Neoplasias Pulmonares/genética; Proteínas Proto-Oncogénicas p21(ras)/genética; Recurrencia Local de Neoplasia; Mutación

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Límite: Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google